🇺🇸 FDA
Patent

US 7807383

Diagnosing and treating hormone resistant cancers

granted A61PA61P35/04

Quick answer

US patent 7807383 (Diagnosing and treating hormone resistant cancers) held by The Board of Regents of the University of Texas System expires Mon Sep 30 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Oct 05 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 30 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61P, A61P35/04